Abbott cuts 700 jobs from device and testing unit

Jan 25, 2012 By MATTHEW PERRONE , AP Health Writer

(AP) -- Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts.

A company spokeswoman said most of the will affect employees who manufacture the company's heart stents and . Abbott has seen a decline in orders for artery-opening stents, ahead of the expiration of a supply agreement with medical device rival Boston Scientific Corp. Abbott currently sells a version of its Xience stent to Boston Scientific, which pays a 40 percent royalty on sales. Boston Scientific recently replaced that device with its own in-house stent, Promus Element.

About 300 of the eliminated positions are at the company's stent in Southern California. Less than 200 others involve the company's diagnostic business in Lake County, Illinois. Other layoffs affect the company's pharmaceutical manufacturing operation in Puerto Rico, among other places. Employees were notified of the cuts by their managers, according to Abbott spokeswoman Adelle Infante.

Abbott has been restructuring its operations for several years, laying off about 1,900 pharmaceutical division employees this time last year. About 1,000 of those terminated positions were in Illinois.

News of the layoffs came several hours after Abbott reported a 12 percent increase in fourth-quarter profit Wednesday, as the blockbuster anti-inflammatory drug Humira continued to dominate the company's performance with double-digit sales growth.

In October, Abbott surprised investors and analysts with the announcement that it would spin off its branded drug business, including Humira. said the split would allow investors to separately value Abbott's businesses, which also include , generic drugs and .

Wednesday's results highlighted the rationale for the split, with top-selling drug Humira dominating the company's results, contributing $2.18 billion, or over 20 percent, of sales.

While Humira has been the key to Abbott's growth, it has also a weighed on the company's stock, overshadowing performance of its other businesses. The drug, which is used to treat psoriasis and rheumatoid arthritis, loses patent protection in 2016, and no obvious successor has appeared in the company's pipeline. The split-up frees Abbott from the risks and obligations of developing innovative pharmaceutical drugs, leaving the company with a more predictable business built around nutritional formula, generic drugs and heart stents.

Abbott earned $1.62 billion, or $1.02 per share, up from $1.44 billion, or 92 cents per share, in the prior-year period. Excluding one-time items, the company earned $1.45 per share, up from $1.30 in the same period a year earlier. Total company sales grew 4.1 percent to $10.38 billion.

Analysts polled by FactSet expect fourth-quarter earnings per share of $1.44 on revenue of $10.59 billion.

For 2012, the North Chicago, Ill., company expects to earn $4.95 to $5.05 per share, compared with the average analyst estimate of $5.02 per share.

The company's branded drug business posted sales of $4.78 billion for the period, an increase of 6.7 percent. The business, which includes the cholesterol drugs Trilipix and Niaspan among other treatments, is scheduled to become a separate business before the end of 2012. The new company will have revenue of roughly $18 billion.

Among Abbott's remaining businesses, slipped 4.6 percent to $1.39 billion. Nutritionals rose 8.6 percent to $1.56 billion while sales of the company's stents and other heart devices were roughly flat at $826 million.

shares fell $1.01 to $54.97 in afternoon trading.

Explore further: Yahoo profit surges on Alibaba divestment, mobile

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Abbott 3Q profit falls on Solvay, Meridia costs

Oct 20, 2010

(AP) -- Drug and medical device maker Abbott Laboratories said Wednesday its third-quarter net income dropped 40 percent on costs connected with its purchase of Solvay Pharmaceuticals and its decision to withdraw the diet ...

CenturyLink 3Q net income falls as expenses rise

Nov 02, 2011

(AP) -- Phone company CenturyLink Inc. says its third-quarter net income fell as rising operating expenses related to its April acquisition of larger phone company Qwest overshadowed increased revenue.

Recommended for you

Turner channels removed from Dish amid pact spat

14 hours ago

Channels such as Cartoon Network and CNN are no longer part of Dish's programming lineup as a deadline has passed for the satellite TV provider and Turner Broadcasting to renew their distribution agreement.

Verizon reports higher 3Q net income, revenue

15 hours ago

Verizon Communications Inc. on Tuesday reported higher net income and revenue in its third quarter, helped by strong wireless subscriber growth and demand for its high-speed FiOS Internet services.

Amazon, Simon & Schuster sign book retail deal

23 hours ago

Amazon has reached a deal with American book publisher Simon & Schuster, the companies said, though the e-commerce giant remains at loggerheads with France's Hachette over e-book pricing.

User comments : 0